Rashid Riaz, MD, Leah Lande, MD, and Dana Zappetti, MD
Synopsis: In this 2-year, multicenter, randomized, double-blind, placebo-controlled trial, the use of tiotropium in patients with chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease stage 1 and stage 2 disease resulted in improved forced expiratory volume in 1 second throughout the trial duration, reduced rate of decline in forced expiratory volume in 1 second after bronchodilator use over 24 months, decreased frequency of exacerbations, and improved quality of life assessments compared with placebo. However, it remains unclear whether the use of tiotropium alters the long-term disease course in patients with chronic obstructive pulmonary disease.
Source: Yumin Zhou, Nan-shan Zhong, Xiaochen Li, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med 2017;377:923–935.